Revolution Medicines Inc

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Year Ended December 31,
	2023	2022	2021
Revenue:
Collaboration revenue	$11,580	$35,380	$29,390
Total revenue	11,580	35,380	29,390
Operating expenses:
Research and development	423,144	253,073	186,948
General and administrative	75,621	40,586	30,450
Total operating expenses	498,765	293,659	217,398
Loss from operations	(487,185)	(258,279)	(188,008)
Other income (expense), net:
Interest income	47,482	9,154	929
Interest and other expense	(303)	—	(12)
Change in fair value of warrant liability and contingent earn-out shares	115	—	—
Total other income, net	47,294	9,154	917
Loss before income taxes	(439,891)	(249,125)	(187,091)
Benefit from income taxes	3,524	420	—
Net loss	$(436,367)	$(248,705)	$(187,091)
Net loss per share attributable to common stockholders, basic and diluted	$(3.86)	$(3.08)	$(2.57)
Weighted-average common shares used to compute net loss per share, basic and diluted	113,149,869	80,626,525	72,806,079
Comprehensive loss:
Net loss	$(436,367)	$(248,705)	$(187,091)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	2,324	(1,404)	(492)
Comprehensive loss	$(434,043)	$(250,109)	$(187,583)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.